Sengenics said this week that it will launch a cancer biomarker discovery and clinical trial immunoresponse monitoring service based on Oxford Gene Technology's functional protein array platform.

Sengenics, based in Kuala Lumpur, Malaysia, said that it will launch the service in the second quarter from a new protein array facility that has been custom built to run the OGT arrays.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.